Advertisement

Advertisement
Gilberto de Lima Lopes, Jr, MD, MBA, and Karen L. Reckamp, MD, on NSCLC: Overall Survival Results With Ramucirumab Plus Pembrolizumab vs Standard of Care

Gilberto de Lima Lopes, Jr, MD, MBA, and Karen L. Reckamp, MD, on NSCLC: Overall Survival Results With Ramucirumab Plus Pembrolizumab vs Standard of Care

Ramucirumab/Pembrolizumab vs Standard of Care in Patients With Advanced NSCLC Previously Treated With Immune Checkpoint Inhibitors

Ramucirumab/Pembrolizumab vs Standard of Care in Patients With Advanced NSCLC Previously Treated With Immune Checkpoint Inhibitors

In the phase II Lung-MAP substudy S1800A presented at the 2022 ASCO Annual Meeting and simultaneously reported in the Journal of Clinical Oncology, Karen L. Reckamp, MD, and colleagues found that the combination of ramucirumab and pembrolizumab improved overall survival vs investigator’s choice of standard-of-care treatment in patients with advanced non–small cell lung cancer (NSCLC) who experienced disease progression on prior immune checkpoint inhibitor therapy.

Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows

Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of the KRYSTAL-1 trial presented by Spira et al at the 2022 ASCO Annual Meeting. The findings were simultaneously published in The New England Journal of Medicine.

 

Intracranial Efficacy of Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC

Intracranial Efficacy of Lorlatinib vs Crizotinib in <em>ALK</em>-Positive Advanced NSCLC

In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system progression were improved with lorlatinib vs crizotinib in previously untreated patients with advanced ALK-positive non–small cell lung cancer (NSCLC) with or without baseline brain metastases.

Addition of Tiragolumab to Atezolizumab in PD-L1–Positive NSCLC

Addition of Tiragolumab to Atezolizumab in PD-L1–Positive NSCLC

In a phase II trial (CITYSCAPE) reported in The Lancet Oncology, Byoung Chul Cho, MD, and colleagues found that the addition of tiragolumab, an inhibitor of the immune checkpoint molecule TIGIT, to atezolizumab improved objective response rate and progression-free survival in first-line treatment of patients with PD-L1–positive recurrent or metastatic non–small cell lung cancer (NSCLC).

Real-World Association Between Smoking History and Overall Survival With First-Line Pembrolizumab in Patients With Advanced NSCLC

Real-World Association Between Smoking History and Overall Survival With First-Line Pembrolizumab in Patients With Advanced NSCLC

In a retrospective cohort study reported in JAMA Network Open, Sanjay Popat, FRCP, PhD, and colleagues found that among patients initiating first-line pembrolizumab for EGFR and ALK wild-type advanced non–small cell lung cancer (NSCLC), ever-smokers had significantly better overall survival vs never-smokers.

Personalized Lung Cancer Risk Assessment Using a Blood-Based Biomarker Panel

In a study reported in the Journal of Clinical Oncology, Fahrmann et al found that a four-component blood-based biomarker panel showed predictive ability for the development of lung cancer. Prediction was improved when the panel was used in conjunction with the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 2012 model of risk assessment for lung cancer screening eligibility.

Advertisement


Advertisement